This site is intended for healthcare professionals only
LoginRegister
Novartis AG to Exit India Arm in Rs 1,446 Cr Deal, ChrysCapital-Led Consortium Buys 70.68% StakeCDSCO Panel Approves Novartis Protocol Amendment Proposal to study Ribociclib
ED arrests man in Rs 3.75 crore psychotropic drug caseRs 220 crore bank fraud case against pharma company: ED conducts searches 8 locations in Mumbai,...
Emcure Pharma Q3 Profit 48% to Rs 231 CrEmcure Pharma launches new dermatology-focused arm Emcutix Biopharma
Nandini PiramalPiramal Pharma deploying USD 85 million capex this fiscal: Nandini Piramal
Sun Pharma Rules Out Big-Bang Acquisitions, Bets on Organic Growth and BiosimilarsSun Pharma presents Leqselvi data highlighting clinical efficacy, durability for Alopecia Areata...
NPPA Panel Defers Biological Es Pneumonia Vaccine Price Exemption, Seeks ClarificationCDSCO Panel approves Biological E's Phase IV clinical trial protocol to study PNEUBEVAX-14
Pill form of Wegovy gets USFDA approval for weight lossCDSCO Panel grants Novo Nordisk Protocol Amendment Proposal to study concizumab
Novartis AG to Exit India Arm in Rs 1,446 Cr Deal, ChrysCapital-Led Consortium Buys 70.68% StakeNovartis' Ribociclib named as Category 1 Preferred Adjuvant Treatment for Breast Cancer in NCCN...
dexcom salesDexcom Beats Quarterly Sales Expectations, Reaffirms Annual Outlook
West Pharmas 2025 Forecast Misses Estimates as Inventory Reductions ContinueWest Pharma Raises 2024 Profit Forecast Amid Surging Demand for Injectable Therapy Supplies
Mylan Laboratories Gets CDSCO Nod to Manufacture and Market Epinephrine tartrate InjectionMylan Laboratories Gets CDSCO Nod to Manufacture and Market Epinephrine tartrate Injection
Johnson and Johnson Agrees to Cut US Drug Prices in Deal with Trump Administration to Avoid TariffsJohnson & Johnson Gets CDSCO Panel Nod to Study anti-cancer drug Amivantamab
X